AR045559A1 - Rapamicina amorfa 42- ester con 3- hidroxi-(hidroximetil)-2 acido metilpropionico y sus composiciones farmaceuticas - Google Patents

Rapamicina amorfa 42- ester con 3- hidroxi-(hidroximetil)-2 acido metilpropionico y sus composiciones farmaceuticas

Info

Publication number
AR045559A1
AR045559A1 ARP040103142A ARP040103142A AR045559A1 AR 045559 A1 AR045559 A1 AR 045559A1 AR P040103142 A ARP040103142 A AR P040103142A AR P040103142 A ARP040103142 A AR P040103142A AR 045559 A1 AR045559 A1 AR 045559A1
Authority
AR
Argentina
Prior art keywords
hydroxy
ester
rapamycin
methylpropionic acid
amorfa
Prior art date
Application number
ARP040103142A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR045559A1 publication Critical patent/AR045559A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Reivindicación 1: Una forma amorfa de rapamicina 42-éster con el ácido 3-hidroxi-2-(hidroximetil)-2-metilpropiónico que tiene las siguientes características: a) un diagrama de picos de difracción de rayos X que comprende un halo ancho a 20 de alrededor de 17°; y b) un termograma de calorimetría de exploración diferencial que no tiene el pico endotérmico de alrededor de 164° de la rapamicina cristalina 42-éster con el ácido -hidroxi-(hidroximetil)-2-metilpropiónico.
ARP040103142A 2003-09-03 2004-09-02 Rapamicina amorfa 42- ester con 3- hidroxi-(hidroximetil)-2 acido metilpropionico y sus composiciones farmaceuticas AR045559A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49978903P 2003-09-03 2003-09-03

Publications (1)

Publication Number Publication Date
AR045559A1 true AR045559A1 (es) 2005-11-02

Family

ID=34272870

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103142A AR045559A1 (es) 2003-09-03 2004-09-02 Rapamicina amorfa 42- ester con 3- hidroxi-(hidroximetil)-2 acido metilpropionico y sus composiciones farmaceuticas

Country Status (25)

Country Link
US (2) US7271177B2 (es)
EP (1) EP1660081A1 (es)
JP (1) JP2007504226A (es)
KR (1) KR20060090803A (es)
CN (1) CN1874771A (es)
AR (1) AR045559A1 (es)
AU (1) AU2004270154A1 (es)
BR (1) BRPI0414066A (es)
CA (1) CA2536775A1 (es)
CO (1) CO5680426A2 (es)
CR (1) CR8293A (es)
EC (1) ECSP066473A (es)
GT (1) GT200400175A (es)
IL (1) IL173786A0 (es)
MX (1) MXPA06002123A (es)
NO (1) NO20061048L (es)
PA (1) PA8611201A1 (es)
PE (1) PE20050945A1 (es)
RU (1) RU2345999C2 (es)
SA (1) SA04250334B1 (es)
SG (1) SG145716A1 (es)
TW (1) TW200510428A (es)
UA (1) UA84881C2 (es)
WO (1) WO2005023254A1 (es)
ZA (1) ZA200601822B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660081A1 (en) * 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
PT1701698E (pt) * 2004-01-08 2008-03-27 Wyeth Corp Composição farmacêutica para a administração oral de cci-779
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
CA2562952A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
MXPA06012404A (es) * 2004-04-27 2007-01-17 Wyeth Corp Marcado de rapamicina usando metilasas especificas de rapamicina.
EP1781672B1 (en) * 2004-08-27 2010-10-06 Cordis Corporation Solvent free amorphous rapamycin
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CA2595766A1 (en) 2005-02-09 2006-08-17 Wyeth Cci-779 polymorph and use thereof
JP2009518413A (ja) * 2005-12-07 2009-05-07 ワイス 精製結晶性ｃｃｉ−７７９を調製するためのプロセス
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
CN101351702A (zh) * 2005-12-07 2009-01-21 惠氏公司 结晶雷帕霉素的制备方法以及使用差示扫描量热法测量雷帕霉素化合物结晶度的方法
CA2634056C (en) * 2005-12-21 2014-06-10 Eisai R&D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080234657A1 (en) * 2007-03-22 2008-09-25 Medtronic Vascular, Inc. Methods for contributing to cardiovascular treatments
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en) 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
US20100227799A1 (en) * 2009-03-09 2010-09-09 Medtronic Vascular, Inc. Simultaneous photodynamic therapy and photo induced polymerization
AU2010247766B2 (en) * 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2821524A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
MX371021B (es) * 2013-08-29 2020-01-13 Cadila Healthcare Ltd Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.
JP6516743B2 (ja) 2013-11-25 2019-05-22 コーセプト セラピューティクス， インコーポレイテッド オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3055076C (en) 2017-03-31 2022-02-22 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
WO2020101675A1 (en) 2018-11-14 2020-05-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
CA3121193C (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
AU2020226863B2 (en) 2019-02-22 2023-04-06 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
EP4072556A4 (en) 2019-12-11 2024-01-03 Corcept Therapeutics Inc METHOD FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
DK1635830T3 (da) * 2002-09-17 2009-02-23 Wyeth Corp Granulatformulering af rapamycinesteren CCI-779
MXPA06000951A (es) * 2003-08-07 2006-03-30 Wyeth Corp Sintesis regioselectiva de cci-779.
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
PT1701698E (pt) 2004-01-08 2008-03-27 Wyeth Corp Composição farmacêutica para a administração oral de cci-779

Also Published As

Publication number Publication date
US20050049271A1 (en) 2005-03-03
MXPA06002123A (es) 2006-05-17
WO2005023254A1 (en) 2005-03-17
CR8293A (es) 2006-07-14
US7446111B2 (en) 2008-11-04
US7271177B2 (en) 2007-09-18
TW200510428A (en) 2005-03-16
EP1660081A1 (en) 2006-05-31
SA04250334B1 (ar) 2008-05-19
JP2007504226A (ja) 2007-03-01
RU2006110568A (ru) 2007-10-10
BRPI0414066A (pt) 2006-10-24
ZA200601822B (en) 2008-12-31
KR20060090803A (ko) 2006-08-16
PE20050945A1 (es) 2005-12-14
SG145716A1 (en) 2008-09-29
UA84881C2 (ru) 2008-12-10
IL173786A0 (en) 2006-07-05
RU2345999C2 (ru) 2009-02-10
CN1874771A (zh) 2006-12-06
CA2536775A1 (en) 2005-03-17
GT200400175A (es) 2005-04-18
CO5680426A2 (es) 2006-09-29
AU2004270154A1 (en) 2005-03-17
PA8611201A1 (es) 2005-05-10
ECSP066473A (es) 2006-10-10
NO20061048L (no) 2006-05-24
US20080070950A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
AR045559A1 (es) Rapamicina amorfa 42- ester con 3- hidroxi-(hidroximetil)-2 acido metilpropionico y sus composiciones farmaceuticas
NO20050455L (no) Parenterale formuleringer inneholdende en rapamycinhydroksyester
EA199700262A1 (ru) Способ получения 2-метилтиенобензодиазепина и его кристаллические формы
DK1635830T3 (da) Granulatformulering af rapamycinesteren CCI-779
ATE417051T1 (de) Polymorphe von clopidogrel-hydrogensulfat
TW200611699A (en) Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
UA85997C2 (en) Use of erythropoietin
BR9907962A (pt) Composição farmacêntica, composto, e, processo para preparar o mesmo
MA24589A1 (fr) Procede nouveau de fabrication de dispersions solides.
DK1127871T3 (da) Nye estere afledt af substituerede phenylcyclohexylforbindelser
CY1109835T1 (el) Πυρανονες χρησιμες ως αναστολεις της atm
CY1114308T1 (el) Παραγωγα της 3-αλκυλο-5-(4-αλκυλ-5-οξο-τετραϋδροφουραν-2-υλο)πυρρολιδιν-2-ονης ως ενδιαμεσες ενωσεις στη συνθεση των υποδοχεων της ρενινης
FR2850741B1 (fr) Procede de fabrication d'un panneau de refroidissement actif en materiau composite thermostructural
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
DE50101861D1 (de) Tocotrienolchinon- zyklisierungsprodukte mit antihypercholesterin wirkung
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
EA200400211A1 (ru) Лиофилизованная композиция 2-метилтиенобензодиазепина
EA200400876A1 (ru) Способ получения производных толуола
DK1480647T3 (da) Mono-ester eller asymmetrisk substituerede di-ester-prodrugs af dopamin-D1 receptoragonister
EA200200630A1 (ru) Способ получения гидрохлорида эпинастина в виде кристаллической модификации с высокой температурой плавления
SE0004055D0 (sv) N-type calcium channel antagonists for the treatment of pain
FR2852746B1 (fr) Systeme de transmission d'energie a haute tension
FR2812473B1 (fr) Procede de fabrication de segments d'un generateur de courant alternatif

Legal Events

Date Code Title Description
FB Suspension of granting procedure